drugset / Trial / NCT05548348
First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation
Phase 2
Unknown
30 enrolled
Chongqing University Cancer Hospital
Army Specialty Medical Center · collabThe Second Affiliated Hospital of Chongqing Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
Furmonertinib, a newly-designed pan-EGFR-TKI with a trifluoroethoxypyridine-based molecule structure, has shown promising clinical efficacy in EGFR Ex19del/L858R/T790M/Ex20ins mutant advanced NSCLC with an acceptable safety profile without new signals from 80mg to 240mg dose level in phase 1-3 clinical trials. Whether EGFR G719X/S768I/L861Q mutation positive advanced NSCLC patients can benefit from first-line furmonertinib 160mg per day has not been reported. This study aims to investigate the efficacy and safety of furmonertinib 160mg per day in EGFR G719X/S768I/L861Q mutant patients under first-line treatment of advanced NSCLC setting.
Timeline
- Start
- 2022-09-26
- Primary completion
- 2023-12-31
- Completion
- 2025-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Firmonertinib | Small molecule | 160 mg | Oral |